关注
Willem van den Brink
Willem van den Brink
Scientist, Netherlands Organisation for Applied Scientific Research
在 tno.nl 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations
Y Yamamoto, PA Välitalo, DJ van den Berg, R Hartman, W van den Brink, ...
Pharmaceutical research 34, 333-351, 2017
842017
Current and future nutritional strategies to modulate inflammatory dynamics in metabolic disorders
W van den Brink, J van Bilsen, K Salic, FPM Hoevenaars, L Verschuren, ...
Frontiers in Nutrition 6, 129, 2019
632019
Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics
ECM de Lange, W van den Brink, Y Yamamoto, WEA de Witte, YC Wong
Expert Opinion on Drug Discovery 12 (12), 1207-1218, 2017
572017
Whole grain wheat consumption affects postprandial inflammatory response in a randomized controlled trial in overweight and obese adults with mild hypercholesterolemia in the …
FPM Hoevenaars, D Esser, S Schutte, MG Priebe, RJ Vonk, ...
The Journal of nutrition 149 (12), 2133-2144, 2019
492019
Digital biomarkers for personalized nutrition: predicting meal moments and interstitial glucose with non-invasive, wearable technologies
WJ van den Brink, TJ van den Broek, S Palmisano, S Wopereis, ...
Nutrients 14 (21), 4465, 2022
262022
Digital resilience biomarkers for personalized health maintenance and disease prevention
W van den Brink, R Bloem, A Ananth, T Kanagasabapathi, A Amelink, ...
Frontiers in Digital Health 2, 614670, 2021
202021
Access to the CNS: biomarker strategies for dopaminergic treatments
WJ van den Brink, S Palic, I Köhler, ECM de Lange
Pharmaceutical research 35, 1-24, 2018
202018
Revealing the neuroendocrine response after remoxipride treatment using multi-biomarker discovery and quantifying it by PK/PD modeling
WJ van den Brink, YC Wong, B Gülave, PH van der Graaf, ECM de Lange
The AAPS Journal 19, 274-285, 2017
152017
Obese older type 2 diabetes mellitus patients with muscle insulin resistance benefit from an enriched protein drink during combined lifestyle intervention: the probe study
WJ Pasman, RG Memelink, J de Vogel-Van den Bosch, ...
Nutrients 12 (10), 2979, 2020
142020
Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats
WJ Van den Brink, J Elassaiss-Schaap, B Gonzalez-Amoros, AC Harms, ...
European Journal of Pharmaceutical Sciences 109, 431-440, 2017
142017
Next generation health claims based on resilience: the example of whole-grain wheat
F Hoevenaars, JW van Der Kamp, W van Den Brink, S Wopereis
Nutrients 12 (10), 2945, 2020
132020
Exploring the potential of personalized dietary advice for health improvement in motivated individuals with premetabolic syndrome: pretest-posttest study
S van der Haar, FPM Hoevenaars, WJ van den Brink, T van den Broek, ...
JMIR Formative Research 5 (6), e25043, 2021
112021
Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics
WJ Van den Brink, T Hankemeier, PH van der Graaf, ECM de Lange
Expert Opinion on Drug Discovery 13 (6), 539-550, 2018
112018
Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents
W van den Brink, A Emerenciana, F Bellanti, O Della Pasqua, ...
Toxicology and Applied Pharmacology 320, 51-59, 2017
102017
Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D2 receptor activation using multi‐biomarker pharmacokinetic/pharmacodynamic modelling
WJ van den Brink, DJ van den Berg, FEM Bonsel, R Hartman, YC Wong, ...
British Journal of Pharmacology 175 (19), 3832-3843, 2018
82018
Mechanism-based biomarker prediction for low-grade inflammation in liver and adipose tissue
JHM van Bilsen, W van den Brink, AM van den Hoek, R Dulos, ...
Frontiers in Physiology 12, 703370, 2021
62021
Carcinogenicity of biopharmaceuticals
M Dempster, K Siezen, B Braak, W van den Brink, A Emerenciana, ...
Genotoxicity and Carcinogenicity Testing of Pharmaceuticals, 125-157, 2015
42015
Blood‐based biomarkers of quinpirole pharmacology: cluster‐based PK/PD and metabolomics to unravel the underlying dynamics in rat plasma and brain
WJ van den Brink, R Hartman, DJ van den Berg, G Flik, ...
CPT: Pharmacometrics & Systems Pharmacology 8 (2), 107-117, 2019
32019
Feasibility of digital phenotyping based on continuous glucose monitoring to support personalized lifestyle medicine in type 2 diabetes
WJ van den Brink, TJ van den Broek, S Wopereis, S Difrancesco, ...
Maturitas, 108188, 2024
2024
Wearable technology for detection of COPD exacerbations: feasibility of the Health Patch
LJA Cuperus, L Bult, CM van Zelst, WJ van den Brink, KRJM Kamstra, ...
ERJ Open Research 10 (6), 2024
2024
系统目前无法执行此操作,请稍后再试。
文章 1–20